Rituximab as Maintenance Therapy in Type 1 Autoimmune Pancreatitis: An Italian Experience. Issue 10 (November 2021)

• Record Type: Journal Article
• Authors: De Marchi, Giulia; de Pretis, Nicolò; Gabrieletto, Enrico Maria; Amodio, Antonio; Davì, Valeria; Crinò, Stefano Francesco; Gabbrielli, Armando; Ciccocioppo, Rachele; Frulloni, Luca
• Is Part Of: Pancreas. Volume 50:Issue 10(2021)
• Page Start: 1363
• Page End: 1367
• Publication Date: 2021-11
• Subjects: autoimmune pancreatitis -- therapy -- maintenance therapy -- rituximab; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000001925
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Objective: Rituximab (RTX) has been proposed for the induction of remission and maintenance therapy in relapsing type 1 autoimmune pancreatitis (AIP). The aim of the study was to describe the use of RTX as maintenance therapy for patients with type 1 AIP. Methods: Patients with type 1 AIP based on the International Consensus Diagnostic Criteria and treated with RTX were selected from our database. Two doses of RTX (1000 mg each) were administered 15 days apart and repeated after 6 months. Results: Eighteen patients were treated with RTX as maintenance therapy. Of these, the involvement of other organs was observed in 16 patients (89%). Eight of the 18 patients (44%) relapsed during follow-up. Median time to relapse after the last infusion was 30 months (range, 12–35 months). No disease relapse was observed in the first year after the last infusion. Probability of disease relapse was 80% between 1 and 3 years from initial treatment. No adverse effects were observed. Conclusions: Rituximab seems be safe and effective for maintenance therapy of type 1 AIP during the first year after completing RTX infusion. However, the probability of disease relapse is high within 1 and 3 years from the last infusion.